Abata Therapeutics
Matthias John is a seasoned professional in the field of molecular biology and biochemistry with extensive experience in analytical development and nucleic acid therapies. Currently serving as Senior Director of Analytical Development at Abata Therapeutics since June 2021, Matthias previously held the position of Head of mRNA Gene Editing at GeneLeap Biotech, where expertise in therapeutic mRNA techniques was introduced. As an independent consulting scientist, Matthias provided valuable guidance on the manufacturing and delivery of nucleic acid therapeutics. Prior roles include Research Fellow and Head of Platform Operations at CRISPR Therapeutics and various senior research positions at Moderna Therapeutics. Matthias holds a Post-Doc degree from Harvard Medical School and a Ph.D. from Université Louis Pasteur (Strasbourg I).
This person is not in any teams
This person is not in any offices
Abata Therapeutics
1 followers
Abata Therapeutics is bringing an entirely new approach to the treatment of autoimmune disease by engineering Tregs as targeted therapies that stop immune-mediated destruction, restore homeostasis – a state of harmony – and promote repair in the affected tissues. In addition to their lead program in progressive MS, Abata has early programs in Type 1 Diabetes (T1D) and inclusion body myositis (IBM). They bring together industry experts and deeply engaged pioneers in Treg biology, T cell receptor and antigen discovery, disease pathogenesis, and molecular and imaging biomarkers.